Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: Pitfalls and solutions

Journal of Immunological Methods

Volumn 268, Issue 2, 2002, Pages 245-258

  Harris, Claire L ^a   Lublin, Douglas M ^b   Morgan, B Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complement; Decay accelerating factor; Fusion protein; Monoclonal antibody

Indexed keywords

ANTIGEN; DECAY ACCELERATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT PROTEIN; REGULATOR PROTEIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSION VECTOR; GENE AMPLIFICATION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METHODOLOGY; MONONUCLEAR CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; SUPERNATANT; SWINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; CHO CELLS; CRICETINAE; EPITOPE MAPPING; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS;

ANIMALIA; SUIDAE; VECTORS;

EID: 0037107497     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00207-7     Document Type: Article

References (22)

1. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 61:1990;1303.
2. Ashkenazi A., Capon D.J., Ward R.H.R. Immunoadhesins. Int. Rev. Immunol. 10:1993;219.
3. Brekke O.H., Michaelsen T.E., Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol. Today. 16:1995;85.
4. Byrn R.A., Mordenti J., Lucas C., Smith D., Marsters S.A., Johnson J.S., Cossum P., Chamow S.M., Wurm F.M., Gregory T., Groopman J.E., Capon D.J. Biological properties of a CD4 immunoadhesin. Nature. 344:1990;667.
5. Charreau B., Cassard A., Tesson L., Le Mauff B., Navenot J.M., Blanchard D., Lublin D., Soulillou J.P., Anegon I. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation. 58:1994;1222.
6. Coyne K.E., Hall S.E., Thompson S., Arce M.A., Kinoshita T., Fujita T., Anstee D.J., Rosse W., Lublin D.M. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149:1992;2906.
7. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19:2001;163.
8. Harris C.L., Morgan B.P. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology. 86:1995;311.
9. Harris C.L., Rushmere N.K., Morgan B.P. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem. J. 341:1999;821.
10. Harris C.L., Spiller O.B., Morgan B.P. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology. 100:2000;462.
11. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495.
12. Manchester M., Valsamakis A., Kaufman R., Liszewski M.K., Alvarez J., Atkinson J.P., Lublin D.M., Oldstone M.B. Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46). Proc. Natl. Acad. Sci. U. S. A. 92:1995;2303.
13. Martinez-Pomares L., Kosco-Vilbois M., Darley E., Tree P., Herren S., Bonnefoy J.Y., Gordon S. Fc chimeric protein containing the cysteine-rich domain of the murine mannose receptor binds to macrophages from splenic marginal zone and lymph node subcapsular sinus and to germinal centers. J. Exp. Med. 184:1996;1927.
14. Morgan B.P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:1994;369.
15. Nicholson-Weller A., Wang C.E. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123:1994;485.
16. Perez de la Lastra J.M., Harris C.L., Hinchliffe S.J., Holt D.S., Rushmere N.K., Morgan B.P. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats. J. Immunol. 165:2000;2563.
17. Phillips M.L., Tao M.H., Morrison S.L., Schumaker V.N. Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol. Immunol. 31:1994;1201.
18. Reid K.B.M., Bentley D.R., Campbell R.D., Chung L.P., Sim R.B., Kristensen T., Tack B.F. Complement proteins which interact with C3b or C4b. A superfamily of structurally related proteins. Immunol. Today. 7:1986;230.
19. Spiller O.B., Harris C.L., Morgan B.P. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J. Immunol. Methods. 224:1999;51.
20. Tan L.K., Shopes R.J., Oi V.T., Morrison S.L. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human-immunoglobulins. Proc. Natl. Acad. Sci. U. S. A. 87:1990;162.
21. van den Berg C.W. Immunoaffinity methods for purification of complement components and regulators. Morgan B.P. Complement Methods and Protocols. 2000;53 Humana Press, Totowa.
22. Xing P.X., Russell S., Prenzoska J., McKenzie J.F. Discrimination between alternatively spliced STP-A and-B isoforms of CD46. Immunology. 83:1994;122.